Nitric oxide- and cisplatin-releasing silica nanoparticles for use against non-small cell lung cancer

Imalka Munaweera; Yi Shi; Bhuvaneswari Koneru; Amit Patel; Mai H Dang; Anthony J Di Pasqua; Kenneth J Balkus Jr

doi:10.1016/j.jinorgbio.2015.09.002

Nitric oxide- and cisplatin-releasing silica nanoparticles for use against non-small cell lung cancer

J Inorg Biochem. 2015 Dec:153:23-31. doi: 10.1016/j.jinorgbio.2015.09.002. Epub 2015 Sep 14.

Authors

Imalka Munaweera¹, Yi Shi², Bhuvaneswari Koneru², Amit Patel², Mai H Dang², Anthony J Di Pasqua³, Kenneth J Balkus Jr⁴

Affiliations

¹ Department of Chemistry, University of Texas at Dallas, 800 West Campbell Rd., Richardson, TX 75080, United States.
² Depatment of Pharmaceutical Sciences, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, United States.
³ Depatment of Pharmaceutical Sciences, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, United States. Electronic address: Anthony.DiPasqua@unthsc.edu.
⁴ Department of Chemistry, University of Texas at Dallas, 800 West Campbell Rd., Richardson, TX 75080, United States. Electronic address: Balkus@utdallas.edu.

PMID: 26402659
DOI: 10.1016/j.jinorgbio.2015.09.002

Abstract

Nitric oxide (NO) and cisplatin releasing wrinkle-structured amine-modified mesoporous silica (AMS) nanoparticles have been developed for the treatment of non-small cell lung cancer (NSCLC). The AMS and NO- and cisplatin-loaded AMS materials were characterized using TEM, BET surface area, FTIR and ICP-MS, and tested in cell culture. The results show that for NSCLC cell lines (i.e., H596 and A549), the toxicity of NO- and cisplatin-loaded silica nanoparticles (NO-Si-DETA-cisplatin-AMS) is significantly higher than that of silica nanoparticles loaded with only cisplatin (Si-DETA-cisplatin-AMS). In contrast, the toxicity of NO-Si-DETA-cisplatin-AMS toward normal lung cell lines is not significantly different from that of Si-DETA-cisplatin-AMS (normal lung fibroblast cells WI-38) or is even lower than that of Si-DETA-cisplatin-AMS (normal lung epithelial cells BEAS-2B). The NO-induced sensitization of tumor cell death demonstrates that NO is a promising enhancer of platinum-based lung cancer therapy.

Keywords: Cisplatin; Mesoporous silica nanoparticles; Nitric oxide; Non-small cell lung cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / chemical synthesis
Antineoplastic Agents / therapeutic use*
Antineoplastic Agents / toxicity
Carcinoma, Non-Small-Cell Lung / drug therapy*
Cell Line, Tumor
Cisplatin / therapeutic use
Cisplatin / toxicity
Drug Carriers / chemistry
Drug Carriers / therapeutic use*
Drug Carriers / toxicity
Humans
Lung Neoplasms / drug therapy*
Mice
Nanoparticles / chemistry
Nanoparticles / therapeutic use*
Nanoparticles / toxicity
Nitric Oxide / therapeutic use
Nitric Oxide / toxicity
Nitric Oxide Donors / chemical synthesis
Nitric Oxide Donors / therapeutic use*
Nitric Oxide Donors / toxicity
Particle Size
Polyamines / chemistry
Silicon Dioxide / chemistry
Silicon Dioxide / therapeutic use
Silicon Dioxide / toxicity
Xenograft Model Antitumor Assays

Substances

Antineoplastic Agents
Drug Carriers
Nitric Oxide Donors
Polyamines
diethylenetriamine
Nitric Oxide
Silicon Dioxide
Cisplatin